Trials / Completed
CompletedNCT06452329
A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
Retrospective Evaluation of Nivolumab in First-Line Unresectable Advanced or Metastatic Gastric Cancer (GC) and Gastroesophageal Junction Cancer (GEJC): A Non-interventional Observational Study in China
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 260 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect and evaluate real-world data to enhance understanding of the effectiveness, and treatment patterns of first-line nivolumab treatment in patients with unresectable advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC) in China
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | As prescribed by treating physician |
Timeline
- Start date
- 2024-02-28
- Primary completion
- 2025-07-29
- Completion
- 2025-07-29
- First posted
- 2024-06-11
- Last updated
- 2025-12-04
Locations
2 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06452329. Inclusion in this directory is not an endorsement.